CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

CRISPR stock offers bold investment potential and how strategic portfolio management can boost resilience and long-term ...

Shares of CRISPR Therapeutics CRSP have rallied 41.4% in the past three months, driven by encouraging data from a study of ...

CRSP is a speculative buy for aggressive investors, driven by the commercial launch and multibillion-dollar potential of ...

CRISPR Therapeutics (NASDAQ:CRSP) stock has been slowly heading lower in recent months, and I don’t think that’s fair. Having reached highs near $90 a share, the stock is now trading at closer ...

Despite my optimism about the long-term prospects of curative gene therapy and CRISPR Therapeutics (NASDAQ:CRSP) stock, a sense of pragmatism and potentially a reality check are in order. Noting ...

The stock price of CRISPR Therapeutics (NASDAQ:CRSP), a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in ...

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year ...

Intellia Therapeutics gains big investor interest as CRISPR pipeline progress fuels optimism despite stock volatility.

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year ...

CRISPR Therapeutics is the company that Piper Jaffray is betting on to win the race, using technology licensed from a University of California, Berkeley, patent for "CRISPR-Cas9" gene editing.